This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DiaDexus, Inc. Adds Two New Directors; Corporate Overview & 3Q Results Webcast Set For November 16, 2010

SOUTH SAN FRANCISCO, Calif., Nov. 9, 2010 /PRNewswire-FirstCall/ -- diaDexus, Inc. (OTC Bulletin Board: DDXS), a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today announced that its Board of Directors has appointed two new independent directors, bringing the total number of directors to seven.  Joining the Board are Karen Drexler, who will chair the Compensation Committee, and Andrew Galligan, who will chair the Audit Committee.

Separately, diaDexus said it will host a webcast on Tuesday, November 16 at 1:30 PM EST ( 10:30 AM PST) to present a corporate overview and discuss its 2010 third quarter financial results. The webcast may be accessed via the company's website at www.diadexus.com/webcast.

Commenting on the new appointments, Chief Executive Officer Patrick Plewman said, "Our two new independent Board members add both financial and commercial expertise in developing and marketing new medical devices and diagnostics. Andrew's career has been focused on strategic finance for life science companies, and in particular, medical devices and diagnostics. Karen adds a commercial dimension having led the company she founded from inception through a successful sale. As we endeavor to grow the business, develop new products and extend our product line, we expect that their experience will complement the expertise already resident on our Board."

Karen Drexler has spent the last 15 years co-founding and building medical device companies, mainly in the diagnostics space.  Karen was President and Chief Executive Officer of Amira Medical, a glucose monitoring company that was sold to Roche in 2001.  She is currently active with CellScape Corporation, Mountain View, CA (Chairperson, co-founder – prenatal diagnostics), Medivoce, Menlo Park, CA (co-founder, President and Board member – patient instructional materials), Orsense, Rehovoth, Israel, (Director – noninvasive patient monitoring) and the Keller Center for Innovation in Engineering Education, Princeton University. She is the holder of 11 issued and two pending patents.

Andrew Galligan is currently Vice President of Finance and Chief Financial Officer of Nevro Corp, a Menlo Park, California–based medical device company with a CE-approved implantable spinal cord stimulation device being commercialized in Europe. Prior to joining Nevro, Andrew held the same position at OOMA  and before that, at Reliant Technologies. He has also held the top financial executive position with Metrika, Corcept Therapeutics, Amira Medical, Molecular Devices and several other medical device companies. Andrew began his career at KPMG.

About diaDexus, Inc. diaDexus, Inc., based in South San Francisco, California, is focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease. The company's PLAC ELISA Test for Lp-PLA2 is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States. For more information, please visit the company's website at www.diaDexus.com

Forward-Looking Statements  

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the company's plans, objectives, expectations and intentions with respect to future operations and products and other statements that are not historical in nature, particularly those that use terminology such as "will," "potential", "could," "can," "believe," "intends," "continue," "plans," "expects," "estimates" or comparable terminology. Forward-looking statements are based on current expectations and assumptions, and entail various known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to diaDexus that could cause actual results to differ materially from those expressed in such forward-looking statements include diaDexus' ability to obtain and maintain regulatory clearance for and successfully commercialize our PLAC Test and new diagnostic products, including getting approval to reintroduce our  PLAC TIA product, shipments of which were suspended in May 2010; diaDexus' ability to demonstrate that treatment of individuals based on their Lp-PLA2 levels improves clinical outcomes in prospective clinical studies; the rate of adoption of the PLAC test by doctors and laboratories; the insurance payer community's acceptance of and reimbursement for the PLAC Test; diaDexus' reliance on sole source third party manufacturers to manufacture and supply our main reagent and the PLAC Test; our ability to retain key employees and to attract, retain and motivate other qualified personnel; diaDexus' limited revenue and cash resources; and diaDexus' significant corporate expenses, including expenses associated with being a public company. Additional factors that could cause diaDexus' results to differ materially from those described in the forward-looking statements can be found in diaDexus' most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and other reports filed with the Securities and Exchange Commission, and available at the SEC's web site at www.sec.gov. The information set forth herein speaks only as of the date hereof, and diaDexus disclaims any intention and does not assume any obligation to update or revise any forward looking statement, whether as a result of new information, future events or otherwise.

SOURCE diaDexus, Inc.

Copyright 2009 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,598.20 -91.66 -0.52%
S&P 500 2,098.04 -5.80 -0.28%
NASDAQ 5,115.3820 -12.8990 -0.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs